Mallinckrodt PLC | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
59
319
325
644
2,134
3,607
Depreciation, Depletion & Amortization
140
276
654
813
808
852
Other Funds
512
9
6
53
18
3,916
Funds from Operations
215
307
863
1,164
1,334
619
Changes in Working Capital
79
67
33
116
189
46
Net Operating Cash Flow
136
373
896
1,185
727
666
Capital Expenditures
148
128
148
183
186
Sale of Fixed Assets & Businesses
-
-
-
267
577
Purchase/Sale of Investments
-
4
3
47
-
Net Investing Cash Flow
235
2,891
2,297
108
318
Issuance/Reduction of Debt, Net
885
2,937
1,122
470
535
Net Financing Cash Flow
373
2,954
1,070
1,162
130
Net Change in Cash
276
432
342
85
918
Free Cash Flow
12
246
748
1,002
541
Deferred Taxes & Investment Tax Credit
9
108
192
433
1,744
542
Net Assets from Acquisitions
88
2,794
2,155
245
76
Other Sources
1
27
3
6
4
Change in Capital Stock
1
8
58
639
648
Exchange Rate Effect
-
1
4
12
3
Extraordinaries
-
-
-
95
418
-

About Mallinckrodt

View Profile
Address
3 Lotus Park
Staines-Upon-Thames Surrey TW18 3AG
United Kingdom
Employees -
Website http://mallinckrodt.com
Updated 07/08/2019
Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments.